Neslihan BAŞÇIL TÜTÜNCÜ, Yıldız KAYA, Ülkü Sibel BENLİ, Ceyda TANOĞLU

Yeni Tanı Tip 2 Diabetes Mellitus Hastalarında Metformin ve Diabetik Diyetin Bilişsel Fonksiyonlara Kısa Dönem Etkisi

Amaç: Çalışmamızda yeni tanı Tip 2 Diabetes Mellitus hastalarında, metformin veya diyet tedavisinin bilişsel işlevler üzerindeki kısa dönem etkilerini araştırmayı amaçladık. Gereç ve Yöntemler: Çalışmamız prospektif olarak tasarlandı. Çalışmaya 64 sağlıklı kontrol ve 72 yeni tanı Tip 2 Diabetes Mellitus hastası dahil edildi. Otuz yedi hasta için metformin tedavisi ve otuz beş hasta için diyet tedavisi tek bir endokrinoloji uzmanı tarafından başlandı. Tüm hastalar için Rey İşitsel Sözel Öğrenme Testi, Rey Kompleks Figur Testi, Sayı Dizisi Testi ve İz Sürme Testi, tanı anında ve tedavinin altıncı ayında tedaviye kör bir nöroloji uzmanı tarafından yapıldı. Bulgular: Sözel bellek skorlarının tanı anında diabet grubunda, sağlıklı kontrollerden anlamlı derecede düşük olduğunu gözlemledik (diyet p= 0.03, metformin p= 0.044). Altıncı ay değerlendirilmesinde, diyet tedavisinin sadece anlık sözel bellek skorlarını anlamlı iyileştirdiği görüldü (p= 0.041). Metformin tedavisi, sözel bellek skorları ile beraber ayrıca görsel uzamsal belleği (p= 0.014), işlem belleği ve yürütücü fonksiyonları (p= 0.036 ve p= 0.001) anlamlı düzeyde iyileştirmiştir. Sonuç: Yeni tanı Tip 2 Diabetes Mellitus hastalarında metformin tedavisi ile sözel bellek, görsel uzamsal bellek ile işlem hızı ve yürütücü işlev skorlarında istatistiksel olarak anlamlı düzeyde iyileşme tespit edilirken, diyet tedavisi ile sadece sözel bellek skorlarında iyileşme gözlenmiştir.

Short-Term Effects of Metformin and Diabetic Diet on Cognitive Functions in Newly Diagnosed Type 2 Diabetes Mellitus Patients

Aim: We aimed to investigate the effects of metformin or dietary treatment on cognitive functions in newly diagnosed Type 2 Diabetes Mellitus patients. Material and Methods: Our study was designed prospective. The study included 64 healthy controls and 72 newly diagnosed Type 2 Diabetes Mellitus patients. Metformin treatment for thirty-seven patients and dietary treatment for thirty-five patients were administered by a single endocrinologist. Rey Auditory Verbal Learning Test, Rey Complex Figure Test, Digit Span Test and Trail Making Test for all patients were performed at the time of diagnosis and at the sixthmonth of the treatment by a blinded neurologist. Results: At the time of diagnosis, we observed that verbal memory scores in the diabetes group were significantly lower than healthy controls (p= 0.03 in dietary, p= 0.044 in metformin group). Sixth- month evaluation revealed that dietary treatment improved only immediate verbal memory scores (p= 0.041). Metformin treatment, along with verbal memory scores, also significantly improved visual spatial memory (p= 0.014) and processing memory and executive functions (p= 0.036 and p= 0.001). Conclusion: We determined a statistically significant improvement in verbal memory, visual spatial memory and processing speed & executive function scores with metformin treatment, while dietary treatment improved only verbal memory scores.

PDF

___

1. Songer TJ, Zimmet PZ. Epidemiology of type II diabetes: An international perspective. Pharmaco Economics 1995;8:1- 11.
2. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends in Neurosciences 2000;23(11):542-549.
3. Nandipati S, Luo X, Schimming C, Grossman HT, Sano M. Cognition in non-demented diabetic older adults. Current Aging Science 2012;5(2):131-135.
4. Saczynski JS, Jonsdottir MK, Garcia ME, Jonsson PV, Peila R, Eiriksdottir G, et al. Cognitive impairment: An increasingly important complication of type 2 diabetes: the age, gene/environment susceptibility-Reykjavik study. Am J Epidemiol 2008;168(10):1132-1139.
5. Qiu C, Sigurdsson S, Zhang Q, Jonsdottir MK, Kjartansson O, Eiriksdottir G, et al. Diabetes, markers of brain pathology and cognitive function: The age, gene/environment susceptibility-reykjavik study. Ann Neurol 2014;75(1):138- 146.
6. Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ. Diabetes and other vascular risk factors for dementia: Which factor matters most? A systematic review. European Journal of Pharmacology 2008;585(1):97-108.
7. Kroner Z. The relationship between alzheimer’s disease and diabetes: Type 3 diabetes? Altern Med Rev 2009;14(4):373- 379.
8. de la Monte SM, Tong M, Lester-Coll N, Jr Plater M, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer’s disease. J Alzheimers Dis 2006;10(1):89-109.
9. Herath PM, Cherbuin N, Eramudugolla R, Anstey KJ. The effect of diabetes medication on cognitive function: Evidence from the PATH through life study. BioMed Research International 2016;2016:7208429.
10. Sims-Robinson C, Kim B, Rosko A, Feldman EL. How does diabetes accelerate alzheimer disease pathology? Nature Reviews Neurology 2010;6(10):551-559.
11. Rivera EJ, Goldin A, Fulmer N, Tavares R, Wands JR, de la Monte SM. Insulin and insulin-like growth factor expression and function deteriorate with progression of alzheimer’s disease: Link to brain reductions in acetylcholine. J Alzheimers Dis 2005;8(3):247-268.
12. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: A systematic review. The Lancet Neurology 2006;5(1):64-74.
13. Cheng C, Lin CH, Tsai YW, Tsai CJ, Chou PH, Lan TH. Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis. J Gerontol A Biol Sci Med Sci 2014;69(10):1299-1305.
14. Bozoki A, Giordani B, Heidebrink JL, Berent S, Foster NL. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Archives of Neurology 2001;58(3):411-416.
15. Brookmeyer R, Gray S, Kawas C. Projections of alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health 1998;88(9):1337-1342.
16. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: An update. Annals of Internal Medicine 2002;137(1):25-33.
17. Adak T, Samadi A, Unal AZ, Sabuncuoglu S. A reappraisal on metformin. Regul Toxicol Pharmacol 2018;92:324-332.
18. Ng TP, Feng L, Yap KB, Lee TS, Tan CH, Winblad B. Longterm metformin usage and cognitive function among older adults with diabetes. J Alzheimers Dis 2014;41(1):61-68.
19. Kickstein E, Krauss S, Thornhill P, Rutschow D, Zeller R, Sharkey J, et al. Biguanide metformin acts on tau phosphorylation via mTOR/protein phosphatase 2A (PP2A) signaling. Proc Natl Acad Sci USA 2010;107(50):21830- 21835.
20. Wang J, Gallagher D, DeVito LM, Cancino GI, Tsui D, He L, et al. Metformin activates an atypical PKC-CBP pathway to promote neurogenesis and enhance spatial memory formation. Cell Stem Cell 2012;11(1):23-35.
21. Chen F, Dong RR, Zhong KL, Ghosh A, Tang SS, Long Y, et al. Antidiabetic drugs restore abnormal transport of amyloidbeta across the blood-brain barrier and memory impairment in db/db mice. Neuropharmacology 2016;101:123-136.
22. Taylor MK, Sullivan DK, Swerdlow RH, Vidoni ED, Morris JK, Mahnken JD, et al. A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults. Am J Clin Nutr 2017;106(6):1463-1470.
23. Dong W, Wang R, Ma LN, Xu BL, Zhang JS, Zhao ZW, et al. Influence of age-related learning and memory capacity of mice: Different effects of a high and low caloric diet. Aging Clin Exp Res 2016;28(2):303-311.
24. Garber A, Csizmadi I, Friedenreich CM, Sajobi TT, Longman RS, Tyndall AV, et al. Association between glycemic load and cognitive function in community-dwelling older adults: Results from the Brain in Motion study. Clin Nutr 2018;37(5):1690-1699.
25. Cheatham RA, Roberts SB, Das SK, Gilhooly CH, Golden JK, Hyatt R, et al. Long-term effects of provided low and high glycemic load low energy diets on mood and cognition. Physiol Behav 2009;98(3):374-379.
26. Abbatecola AM, Lattanzio F, Molinari AM, Cioffi M, Mansi L, Rambaldi P, et al. Rosiglitazone and cognitive stability in older individuals with type 2 diabetes and mild cognitive impairment. Diabetes Care 2010;33(8):1706-1711.
27. Wennberg AMV, Hagen CE, Edwards K, Roberts RO, Machulda MM, Knopman DS, et al. Association of antidiabetic medication use, cognitive decline, and risk of cognitive impairment in older people with type 2 diabetes: Results from the population-based Mayo Clinic Study of Aging. Int J Geriatr Psychiatry 2018;33(8):1114-1120.
28. Mahler RJ, Adler ML. Clinical review 102: Type 2 diabetes mellitus: Update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999;84(4):1165-1171.
29. Bayraktar M. Diabetes mellitus tedavisinin genel ilkeleri, diyet ve egzersiz. Türkiye Tıp Derg 2001;8:9-19. 30. Lezak M. Neuropsychological testing. University Press, Oxford; 1995.
31. Boone KB, Lesser IM, Hill-Gutierrez E, Berman NG, D’elia LF. Rey-osterrieth complex figure performance in healthy, older adults: Relationship to age, education, sex, and IQ. The Clinical Neuropsychologist 1993;7(1):22-28.
32. Hale JB, Hoeppner J-AB, Fiorello CA. Analyzing digit span components for assessment of attention processes. Journal of Psychoeducational Assessment 2002;20(2):128-143.
33. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections. Diabetes Care 1998;21(9):1414-1431.
34. Onar B, Özaçmak HS, Turan İ, Özaçmak VH. Diyabete bağlı kognitif bozukluk sıçanların hipokampüslerinde NLRP3 ve nitrotirozin seviyelerinin artışı ile ilişkilidir. Türkiye Diyabet ve Obezite Dergisi 2019;3(3):123-129.
35. Gupta A, Bisht B, Dey CS. Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and alzheimer’s-like changes. Neuropharmacology 2011;60(6):910-920.
36. Koenig AM, Mechanic-Hamilton D, Xie SX, Combs MF, Cappola AR, Xie L, et al. Effects of the insulin sensitizer metformin in alzheimer disease: Pilot data from a randomized placebo-controlled crossover study. Alzheimer Dis Assoc Disord 2017;31(2):107-113.
37. Chen Y, Zhou K, Wang R, Liu Y, Kwak YD, Ma T, et al. Antidiabetic drug metformin (GlucophageR) increases biogenesis of alzheimer’s amyloid peptides via up-regulating BACE1 transcription. Proceedings of the national academy of sciences of the United States of America 2009;106(10):3907-3912.
38. Thangthaeng N, Rutledge M, Wong JM, Vann PH, Forster MJ, Sumien N. Metformin impairs spatial memory and visual acuity in old male mice. Aging and Disease 2017;8(1):17- 30.
39. Imfeld P, Bodmer M, Jick SS, Meier CR. Metformin, other antidiabetic drugs, and risk of alzheimer’s disease: A population-based case-control study. J Am Geriatr Soc 2012;60(5):916-921.
40. Kuan YC, Huang KW, Lin CL, Hu CJ, Kao CH. Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus. Prog Neuropsychopharmacol Biol Psychiatry 2017;79(Pt B):77- 83.
41. Moore EM, Mander AG, Ames D, Kotowicz MA, Carne RP, Brodaty H, et al. Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes care 2013;36(10):2981-2987.